Nephrocare Health IPO Details
| IPO Open Date | December 10, 2025 |
| IPO Close Date | December 12, 2025 |
| Face Value | ā¹2 Per Equity Share |
| IPO Price Band | ā¹438 to ā¹460 Per Share |
| Issue Size | Approx ā¹871.05 Crores |
| Fresh Issue | Approx ā¹353.40 Crores |
| Offer for Sale: | Approx 1,12,53,102 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE, NSE |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Nephrocare Health IPO Review & Key Points
- Review: May Apply
- Rating: 4
Nephrocare Health IPO Market Lot
The Nephrocare Health IPO minimum market lot is 32 shares with ā¹14,720 application amount. The retail investors can apply up-to 13 lots with 416 shares of ā¹1,91,360 amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 32 | ā¹14,720 |
| Retail Maximum | 13 | 416 | ā¹1,91,360 |
| S-HNI Minimum | 14 | 448 | ā¹2,06,080 |
| S-HNI Maximum | 67 | 2,144 | ā¹9,86,240 |
| B-HNI Minimum | 68 | 2,176 | ā¹10,00,960 |
IPO Reservation
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | 56,57,919 Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Nephrocare Health IPO Anchor Investors
| Anchor Bidding Date | December 9, 2025 |
| Anchor Investors List | |
| Shares Offered | 56,57,919 Shares |
| Anchor Size | 260.26 Cr. |
| lock-in period end date 50% shares (30 Days) | January 14, 2026 |
| lock-in period end date 50% shares (90 Days) | March 15, 2026 |
Nephrocare Health IPO Dates
The Nephrocare Health IPO date is December 10 and the close date is December 12. The Nephrocare Health IPO allotment will be finalized on December 15 and the IPO listing on December 17.
| IPO Open Date: | December 10, 2025 |
| IPO Close Date: | December 12, 2025 |
| Basis of Allotment: | December 15, 2025 |
| Refunds: | December 16, 2025 |
| Credit to Demat Account: | December 16, 2025 |
| IPO Listing Date: | December 17, 2025 |
| IPO Bidding Cut-off Time: | December 12, 2025 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Vikram Vuppala, Bessemer Venture Partners Trust, Edoras Investment Holdings Pte. Ltd., Healthcare Parent Limited, Investcorp Private Equity Fund Ii And Investcorp Growth Opportunity Fund.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 9,26,50,799 | 78.90% |
| Promoter Holding Post Issue | 10,03,33,516 | 71.49% |
Objects of the Issue & Utilisation of proceeds
| Purpose | Crores |
| Capital expenditure by the Company for opening new dialysis clinics in India and | ā¹129.11 |
| Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company | ā¹136 |
| General corporate purposes | ā¹- |
About Nephrocare Health IPO
Nephrocare Health Services Ltd. has been in the business of offering end-to-end dialysis care since 2010, with a large network of clinics across India and international markets. Diagnosis, haemodialysis, home and mobile dialysis, and wellness programs are among the services provided by Nephrocare, which also has its own pharmacy.
The company runs a total of 490 clinics, 447 in India and 43 across the Philippines, Uzbekistan, and Nepal as of March 31, 2025. Currently, the business is present in 269 towns in 21 Indian states and four union territories.
As of March 2025, the company had 5068 dialysis machines serving 29,281 patients and performing over 2.88 million dialysis sessions. Max, Fortis Escorts, Care Hospitals, Wockhardt, Paras, CMRI, Jehangir Hospital, and Ruby Hall Clinic are some of the major hospitals the company partnered with to run an in-house dialysis center.
Nephrocare Health IPO Company Financial Report
Amount ā¹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ā¹443.26 | ā¹451.85 | ā¹11.79 | ā¹666.23 |
| 2024 | ā¹574.72 | ā¹541.56 | ā¹35.13 | ā¹806.02 |
| 2025 | ā¹769.92 | ā¹682.48 | ā¹67.10 | ā¹996.46 |
| September 2025 | ā¹483.97 | ā¹456.07 | ā¹14.23 | ā¹1,193.68 |
Nephrocare Health IPO Valuation – FY2025
Check Nephrocare Health IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 13.45% |
| ROCE: | -% |
| EBITDA Margin: | 22.05% |
| PAT Margin: | 8.88% |
| Debt to equity ratio: | 0.58 |
| Earning Per Share (EPS): | ā¹8.28 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 13.19% |
| Net Asset Value (NAV): | ā¹59.56 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Narayana Health | 38.90 | 50.62 | NA | NA | 5,482.98 Cr. |
| Jupiter Life Line Hospitals | 29.47 | 51.27 | 14.27% | 192.55 | 1,261.55 Cr. |
| Rainbow Children Hospital | 23.97 | 64.00 | 16.56% | 134.67 | 1,515.87 Cr. |
| Dr. Agarwalās Healthcare | 2.80 | 155.32 | NA | NA | 1,711 Cr. |
| Vijaya Diagnostics | 13.95 | 73.20 | NA | NA | 681.39 Cr. |
| Dr. Lal Path Labs | 58.48 | 50.75 | 22.30% | 244.39 | 2,461.40 Cr. |
| Metropolis Healthcare | 28.29 | 73.10 | NA | NA | 1,331.20 Cr. |
IPO Lead Managers aka Merchant Bankers
- ICICI Securities Ltd.
- Ambit Pvt.Ltd.
- IIFL Capital Services Ltd.
- Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Company Address
Nephrocare Health Services Ltd.
5 th Floor, D Block, iLabs Centre,
Plot 18, Software Units Layout,
Survey No. 64, Madhapur, Shaikpet,
Hyderabad, Telangana, 500081
Phone: +91 40 4240 8039
Email: [email protected]
Website: http://www.nephroplus.com/
IPO Registrar
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: [email protected]
Website: https://ipostatus.kfintech.com/
Nephrocare Health IPO FAQs
What is Nephrocare Health IPO?
When Nephrocare Health IPO will open for subscription?
What is Nephrocare Health IPO Investors Portion?
How to Apply the Nephrocare Health IPO?
What is Nephrocare Health IPO Issue Size?
What is Nephrocare Health IPO Price Band?
What is Nephrocare Health IPO Lot Size?
What is the Nephrocare Health IPO Allotment Date?
What is the Nephrocare Health IPO Listing Date?
Note: The Nephrocare Health IPO price band and date are officially announced. The (Nephrocare Health IPO grey market premium) will be added to the IPO GMP page as it will start).
